

CLAIMS

1. Defective recombinant adenovirus containing,
inserted into its genome, a nucleic acid coding for a
tumour-specific protein or peptide capable of inducing
5 an immune protection and a destruction of the
corresponding tumour cells by the immune system.


2. Defective recombinant adenovirus according to
claim 1, characterized in that it contains a nucleic
acid coding for a protein or peptide specific to a
10 human tumour.

3. Defective recombinant adenovirus according to
claim 1 or 2, characterized in that the nucleic acid
inserted into its genome codes for all or part of an
antigen specific to a melanoma.

4. Adenovirus according to claim 3,
characterized in that the nucleic acid in question
codes for a fragment of an antigen specific to a human
melanoma comprising the portion presented to the CTL in
combination with MHC-I molecules.

5. Adenovirus according to one of the preceding
claims, characterized in that the nucleic acid codes
for a protein, or a peptide derived therefrom, selected
from the proteins Mage-1, Mage-3, Bage, Rage and Gage.

6. Defective recombinant adenovirus comprising,
25 inserted into its genome, a nucleic acid coding for a
peptide of the protein Mage-1 or Mage-3 comprising the
portion presented to the CTL.



7. Defective recombinant adenovirus comprising, inserted into its genom , th s quence SEQ ID No. 1.

8. Defective recombinant adenovirus comprising, inserted into its genome, the sequence lying between
5 residues 55 and 82 of the sequence SEQ ID No. 1.

9. Defective recombinant adenovirus comprising, inserted into its genome, the sequence SEQ ID No. 2.

10. Adenovirus according to one of the preceding claims, characterized in that it is chosen
10 from the human serotypes Ad2 and Ad5.

11. Adenovirus according to one of claims 1 to 9, characterized in that it is chosen from canine serotypes.

12. Adenovirus according to one of the
15 preceding claims, characterized in that it contains a deletion in the E1 region.

13. Adenovirus according to claim 11, characterized in that it contains, in addition, a deletion in the E4 region.

20 14. Adenovirus according to one of the preceding claims, characterized in that the nucleic acid is inserted into the E1 or E3 or E4 region.

15. Pharmaceutical composition comprising at least one adenovirus according to one of the preceding
25 claims.

16. Use of an adenovirus according to one of claims 1 to 14, for the in vitro or ex vivo production of cytotoxic lymphocytes specific for human tumours.

10

17. Composition comprising cells infected with a defective recombinant adenovirus according to one of claims 1 to 14.

18. Composition according to claim 17,
5 characterized in that it comprises antigen presenting cells (APC) infected with a defective recombinant adenovirus according to one of claims 1 to 14.

19. Method of preparing cytotoxic T cells specific for a tumour antigen comprising bringing a CTL
10 cell precursor into contact with a population of cells infected with a virus according to one of claims 1 to 14.

a

add
Q1
R2
D1